Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seongnam
Clinical trial register · South Korea

Clinical Trials in Seongnam, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company19 Merck Sharp & Dohme LLC16 AbbVie13 Pfizer12 Boehringer Ingelheim11
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Seongnam

205 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Busan, Jeonju, Seongnam, Seongnam-si, Seoul, Suwon, Yangsan
2026-09-29
Recruiting
Boehringer Ingelheim
Phase 3
466
Bucheon-si, Gyeonggi-do, Busan, Seongnam, Seoul
2026-09-17
Not yet open
Eli Lilly and Company
Phase 3
170
Bucheon-si, Deagu, Junggu, Seongnam, Seoul
2026-09
Recruiting
Eli Lilly and Company
Phase 3
2,001
Ansan-si, Anyang-si, Busan, Guri-si, Gwangju, Junggu, Seogu, Seongnam
2026-08-26
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Daegu, Daejeon, Seongnam, Seoul
2026-08-05
Recruiting
Sanofi
Observational
706
Busan, Daegu, Goyang, Gwangju, Hanam, Iksan, Seongnam, Seoul
2026-07-01
Recruiting
Junyeop Lee
Phase 4
64
Seongnam, Seoul
2026-06-29
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 3
784
Busan, Hwasun, Seongnam, Seoul
2026-06-24
Recruiting
AbbVie
Phase 3
990
Busan, Incheon, Seongnam, Suwon, Hwasun-gun, Seoul
2026-05-22
Recruiting
Transition of Care in Pediatric Rare Endocrine Disorders
NCT07786142Endocrine Disorder, Rare Disorders
Seoul National University Hospital
Not applicable
150
Daegu, Daejeon, Gwangju, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2026-05-20
Recruiting
Dong-A ST Co., Ltd.
Phase 1
51
Seongnam, Seoul
2026-05-18
Recruiting
BioNTech SE
Phase 1/2
533
Seongnam, Seoul
2026-03-30
Recruiting
Bristol-Myers Squibb
Phase 3
850
Cheongju-si, Seongnam, Seoul
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Seongnam, Seoul
2026-03-13
Recruiting
Incyte Corporation
Phase 3
700
Changwon-si, Goyang-si, Seongnam, Seongnam-si, Seoul, Suwon
2026-03-05
Not yet open
Doxycycline vs. Macrolide for MRMP (DOMINO)
NCT07306234Mycoplasma Pneumoniae, Mycoplasma Pneumoniae Pneumonia
DrugsDoxycycline·Azithromycin
Young June Choe
Phase 4
208
Busan, Changwon, Gwangju, Jeju City, Seongnam, Seoul
2026-03-01
Recruiting
Eli Lilly and Company
Phase 3
1,980
Namdong-gu, Seogu, Seongnam, Seoul, Yangsan
2026-02-06
Recruiting
Boehringer Ingelheim
Phase 3
400
Goyang, Seongnam, Seoul, Suwon
2026-01-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Cheongju-si, Goyang-si, Seongnam, Suwon, Seoul
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Seongnam, Goyang-si, Seoul, Deagu
2025-12-31
Recruiting
Jaseng Medical Foundation
Not applicable
96
Seoul, Bucheon-si, Seongnam
2025-12-17
Recruiting
Eli Lilly and Company
Phase 3
1,035
Ansan-si, Guri-si, Gwangju, Seongnam, Seoul
2025-12-15
Recruiting
Ascendis Pharma A/S
Phase 3
186
Sejong, Seongnam, Seoul, Suwon
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Goyang-si, Junggu, Namdong-gu, Seongnam, Seoul
2025-12-12
Recruiting
Kukje Pharma
Phase 3
188
Seongnam
2025-12-09
Recruiting
Boehringer Ingelheim
Phase 3
120
Daegu, Gwangju, Seongnam, Seoul
2025-12-09
Recruiting
NOBO Medicine
Phase 1
9
Hwasun, Seongnam, Seoul, Ulsan
2025-12-02
Recruiting
Eli Lilly and Company
Phase 3
7,140
Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul, Ulsan
2025-12-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Hwasun-gun, Seongnam, Taejŏn, Seoul
2025-11-26
Recruiting
Boehringer Ingelheim
Phase 3
670
Busan, Daejoen, Goyang, Hwasun, Seongnam, Seoul
2025-11-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Cheongju-si, Goyang-si, Seongnam, Suwon, Seoul
2025-11-05
Recruiting
Boryung Pharmaceutical Co., Ltd
Observational
3,000
Seongnam
2025-10-30
Recruiting
Aptabio Therapeutics, Inc.
Phase 1
110
Seongnam, Seoul
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Cheongju-si, Goyang-si, Jinju, Seongnam, Seoul, Suwon
2025-10-24
Recruiting
CHA University
Phase 1
10
Seongnam
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Daegu, Goyang-si, Seongnam, Seoul, Suwon
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
Pfizer
Phase 2/3
982
Incheon, Seongnam, Seongnam-si, Seoul, Daegu, Busan
2025-10-03
Recruiting
Pfizer
Phase 3
680
Cheongju-si, Goyang-si, Seongnam, Seongnam-si, Suwon, Haeundae-gu, Dongjak-gu, Seoul
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Goyang-si, Seongnam, Seoul, Junggu
2025-09-28
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Seongnam, Seoul
2025-09-13
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Goyang-si, Seongnam, Seoul, Daegu
2025-09-11
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Busan, Daejeon, Goyang, Seongnam, Seoul, Suwon
2025-09-08
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Daegu, Gwangju, Namdong-gu, Seongnam, Seoul, Suwon, Ulsan
2025-09-02
Recruiting
Bilix Co.,Ltd.
Phase 2
50
Daegu, Seongnam, Seoul, Yangsan
2025-08-26
Recruiting
ABL Bio, Inc.
Phase 1/2
65
Seongnam, Seoul
2025-08-06
Recruiting
Pusan National University Yangsan Hospital
Phase 2
186
Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2025-07-23
Recruiting
Pfizer
Phase 3
714
Hwasun-gun, Seongnam, Suwon, Busan, Haeundae-gu, Seoul, Deagu
2025-07-23
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Ansan-si, Bucheon-si, Busan, Daejeon, Daejoen, Gwangju, Incheon, Seongnam
2025-07-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Seongnam, Gangnam-gu, Jongno-Gu, Seoul
2025-07-21
Recruiting
Daiichi Sankyo
Phase 2
130
Busan, Daegu, Goyang-si, Incheon, Jeonju, Seongnam, Seoul, Suwon
2025-07-18
Recruiting
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT07002164Myocardial Infarction (MI), Heart Failure
Chonnam National University Hospital
Not applicable
780
Changwon, Daegu, Daejeon, Gwangju, Jeonju, Jinju, Pusan, Seongnam
2025-07-15
Recruiting
Bristol-Myers Squibb
Phase 3
586
Gwangju, Seongnam, Seoul
2025-07-14
Recruiting
Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy
NCT06984952Enhanced Recovery After Surgery, Gastrectomy for Gastric Cancer
Seoul National University Hospital
Not applicable
308
Busan, Daegu, Daejeon, Goyang, Seongnam, Seoul, Suwon
2025-06-13
Recruiting
BioNTech SE
Phase 3
480
Changwon, Daegu, Goyang, Seongnam, Seongnam-si, Seoul
2025-06-10
Recruiting
AbbVie
Phase 2
110
Goyang-si, Seongnam, Seongnam-si, Daegu, Seoul
2025-05-28
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Busan, Gwangju, Incheon, Seongnam, Seoul, Wŏnju
2025-05-20
Recruiting
Imjudo & Imfinzi PMS
NCT06544629Hepatocellular Carcinoma
AstraZeneca
Observational
246
Busan, Goyang, Seongnam, Seoul, Suwon
2025-04-14
Recruiting
Gilead Sciences
Phase 3
695
Changwon-Si, Gwangju, Seongbuk-Gu, Seongnam, Seoul, Suwon, Ulsan
2025-04-04
Recruiting
Pfizer
Phase 3
674
Cheonan-si, Jeonju, Seongnam, Busan, Seoul, Daegu
2025-04-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Goyang-si, Seongnam, Daegu, Seoul
2025-03-16
Active, closed
Celgene
Phase 3
960
Goyang-si, Seongnam, Seoul
2025-03-13
Recruiting
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
NCT06687941Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms
DrugAST-201
Aptamer Sciences, Inc.
Phase 1
70
Goyang-si, Seongnam, Seoul
2025-03-11
Recruiting
APIXABAN App Study
NCT06903845Atrial Fibrillation
Dong-Ju Choi
Not applicable
40
Seongnam
2025-03-01
Recruiting
Daiichi Sankyo
Phase 3
726
Cheongju-si, Daegu, Goyang-si, Hwasun-gun, Incheon, Jeonju, Seongnam, Seongnam-si
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Cheongju-si, Seongnam, Suwon, Seoul, Daegu
2025-02-25
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hwasun-gun, Busan, Daegu, Seongnam, Seoul
2025-01-29
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Busan, Goyang-si, Hwasun, Seongnam, Seoul
2025-01-28
Recruiting
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
NCT06365840TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
DrugDanburstotug
ImmuneOncia Therapeutics Inc.
Phase 2
30
Goyang, Seongnam, Seoul
2025-01-13
Active, closed
Pfizer
Phase 3
1,035
Seongnam-si, Incheon, Goyang-si, Seongnam, Gangnam-gu, Seoul
2025-01-06
Not yet open
HUINNO Co., Ltd
Not applicable
270
Busan, Seongnam, Seoul
2025-01-06
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
DrugsKeytruda·Pembrolizumab
Alnylam Pharmaceuticals
Phase 1
158
Busan, Seongnam, Seoul
2024-12-30
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
Seongnam, Seoul
2024-12-19
Recruiting
Institut de Recherches Internationales Servier
Phase 1/2
52
Seongnam, Seoul
2024-12-16
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Hwasun, Seongnam, Seoul
2024-12-13
Active, closed
HanAll BioPharma Co., Ltd.
Phase 4
50
Ansan, Jeonju, Kwangju, Seongnam, Seoul, Suwon
2024-12-12
Active, closed
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
NCT06712615Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
DrugPG-102
ProGen. Co., Ltd.
Phase 2
144
Bucheon-si, Daegu, Daejeon, Seongnam, Seoul
2024-12-05
Recruiting
NOBO Medicine
Phase 2
33
Busan, Hwasun, Ilsan, Seongnam, Seoul, Ulsan
2024-11-25
Recruiting
Genentech, Inc.
Phase 1
410
Seongnam, Seoul
2024-11-14
Active, closed
AstraZeneca
Phase 2
194
Seongnam, Seoul, Suwon
2024-08-27
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
Seongnam, Seoul
2024-08-07
Recruiting
CHA University
Phase 4
490
Seongnam-si, Daegu, Iksan, Ilsan, Seongnam, Seoul, Wŏnju
2024-08-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Wŏnju, Gwangju, Seongnam, Suwon, Cheongju-si, Busan, Haeundae-gu, Daegu
2024-08-05
Active, closed
Yuhan Corporation
Phase 1
94
Seongnam
2024-07-29
Active, closed
AbbVie
Phase 3
1,400
Busan, Cheonan-si, Ansan-si, Seongnam, Seoul
2024-06-27
Active, closed
Celgene
Phase 3
850
Goyang-si, Seongnam, Suwon, Busan, Seoul, Deagu
2024-06-19
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Bucheon-si, Busan, Cheongju-si, Daejeon, Deagu, Gwangju, Incheon, Seongnam
2024-06-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Goyang-si, Seongnam, Suwon, Pusan, Cheongju-si, Busan, Daegu, Junggu
2024-06-11
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Bucheon-si, Seongnam, Seoul
2024-05-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
450
Seongnam, Seoul
2024-05-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2024-04-03
Recruiting
Verastem, Inc.
Phase 3
270
Seongnam, Seoul
2024-03-18
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Ansan-si, Anyang-si, Bucheon-si, Gwangju, Seongnam, Seoul
2024-03-09
By invitation
Active Surveillance for Low-risk Papillary Thyroid Carcinoma
NCT06261190Thyroid Cancer, Papillary Thyroid Carcinoma
National Cancer Center, Korea
Observational
499
Goyang-si, Seongnam, Seoul
2024-03-06
Recruiting
Hee Young Ju
Phase 2
116
Seoul, Yangsan, Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Suwon
2024-03-05
Active, closed
Eli Lilly and Company
Phase 3
17,300
Bucheon-si, Daegu, Daejeon, Dongjak-gu, Gwangju, Namdong-gu, Seongnam, Seoul
2024-03-05
Not yet open
Effect of Sufentanil on the Postoperative Pain
NCT06260046Postoperative Pain, Acute
DrugsRemifentanil·Sufentanil
Seoul National University Hospital
Not applicable
48
Seongnam
2024-03-01
Recruiting
Daiichi Sankyo
Phase 2/3
860
Goyang-si, Seongnam, Seongnam-si, Seoul
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Daegu, Gyeonggi-do, Seongnam, Seoul
2024-02-26
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
180
Daegu, Seongnam, Seongnam-si, Incheon, Seoul
2024-01-31
Active, closed
Seoul National University Hospital
Not applicable
1,896
Seongnam, Seoul, Suwon
2024-01-29
Recruiting
Neuracle Science Co., LTD.
Phase 1/2
138
Bucheon-si, Gwangju, Ilsan, Pusan, Pyeongchon, Seongnam, Seoul, Suwon
2024-01-19
Active, closed
Samsung Bioepis Co., Ltd.
Phase 1
163
Ansan, Busan, Daegu, Hwasun, Incheon, Jinju, Seongnam, Seoul
2024-01-16
Recruiting
The EMPA-FIT Study
NCT06846411Diabetes, Diabetes Mellitus, Type II
DrugsMetformin·Dapagliflozin
Seoul National University Bundang Hospital
Phase 4
46
Seongnam
2024-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Seongnam, Seoul
2023-12-31
Active, closed
Bristol-Myers Squibb
Phase 3
190
Cheongju-si, Seongnam, Seoul
2023-12-21
Recruiting
Double Unit Cord Blood Transplant in Hematologic Malignancies.
NCT06712108Adult Double Unit Cord Blood Transplant
Seoul National University Hospital
Observational
40
Jeonju, Daegu, Pusan, Seongnam, Seoul
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Goyang-si, Seongnam, Buk-gu, Pusan, Seoul
2023-12-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Seongnam, Seoul
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2023-12-06
Active, closed
AstraZeneca
Phase 3
1,902
Daegu, Goyang-si, Seongnam, Seoul
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hwasun, Goyang-si, Seongnam, Suwon, Yangsan, Cheongju-si, Busan, Junggu
2023-11-12
Recruiting
ABL Bio, Inc.
Phase 1
96
Seongnam, Seoul
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 2
227
Pusan, Daejeon, Gwangju, Seongnam, Junggu, Seoul, Daegu
2023-11-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Seongnam, Suwon, Busan, Daegu, Seoul
2023-10-09
Active, closed
AbbVie
Phase 2
130
Seongnam, Seongnam-si, Hwasun-gun, Seoul
2023-09-21
Recruiting
Gilead Sciences
Phase 3
402
Busan, Daegu, Gwangju, Seongnam, Seoul
2023-09-07
Recruiting
Vividion Therapeutics, Inc.
Phase 1
290
Goyang, Incheon, Seongnam, Seoul, Suwon
2023-07-28
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Busan, Daegu, Jinju, Seongnam, Seoul
2023-07-05
Active, closed
AbbVie
Phase 3
1,328
Ansan-si, Seongnam, Seoul
2023-06-21
Active, closed
Gilead Sciences
Phase 3
654
Gangnam-Gu, Goyang-si Gyeonggi-do, Gyeongsangbuk-do, Incheon, Seongnam, Seoul
2023-05-08
Active, closed
Servier Affaires Médicales
Phase 3
299
Seongnam, Seoul
2023-05-03
Active, closed
AbbVie
Phase 3
520
Goyang-si, Seongnam, Seongnam-si, Daegu, Seoul
2023-03-15
Recruiting
BPH Global Registry
NCT05543200Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Société Internationale d'Urologie
Observational
7,500
Seongnam
2023-03-13
Recruiting
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
DrugsTU2218·Keytruda·Pembrolizumab
TiumBio Co., Ltd.
Phase 1/2
140
Seongnam, Seoul, Suwon
2023-03-10
Active, closed
Pfizer
Phase 3
624
Namdong-gu, Goyang-si, Seongnam, Suwon, Seoul
2023-03-03
Recruiting
Seoul National University Hospital
Phase 3
236
Busan, Daegu, Goyang, Hwasun, Seongnam, Seoul, Suwon
2022-12-15
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Busan, Goyang-si, Hwasun, Seongnam, Seoul
2022-12-15
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Cheongju-si, Goyang-si, Incheon, Jeollanam-do, Seongnam, Seoul
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Busan, Incheon, Jeonju, Seongnam, Seoul, Wŏnju
2022-12-05
Active, closed
AbbVie
Phase 1
288
Goyang-si, Seongnam, Hwasun-gun, Seoul
2022-12-05
Active, closed
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
DrugsPhesgo·Paraplatin·Pertuzumab·Taxol
National Cancer Institute (NCI)
Phase 3
360
Dalseo-gu, Seoul, Seongnam
2022-11-16
Recruiting
Pfizer
Phase 3
1,060
Hwasun-gun, Seongnam, Seoul
2022-11-10
Active, closed
Eli Lilly and Company
Phase 3
15,374
Ansan-si, Busan, Seongnam, Seoul, Wŏnju
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Recruiting
Celgene
Phase 3
810
Busan, Seongnam, Hwasun, Seoul
2022-09-20
Recruiting
Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent
NCT05044273Coronary Artery Disease, Cardiovascular Diseases, Heart Diseases, Myocardial Ischemia
Jung-min Ahn
Observational
2,000
Anyang, Busan, Changwon, Daegu, Gangneung, Gwangju, Iksan, Seongnam
2022-09-01
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
220
Daegu, Goyang-si, Seongnam, Seoul
2022-08-04
Active, closed
Daiichi Sankyo
Phase 3
586
Cheongju-si, Goyang, Seongnam, Seoul
2022-07-08
Recruiting
Adagene Inc
Phase 1/2
186
Seogu, Seongnam, Suwon, Cheongju-si, Seoul, Daegu
2022-06-15
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
83
Busan, Cheongju-si, Gyeonggi-do, Seongnam, Seongnam-si, Seoul
2022-05-30
Active, closed
Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry)
NCT05369182Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease
Samsung Medical Center
Observational
1,003
Gwangju, Jinju, Seongnam, Seoul
2022-04-22
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Busan, Daegu, Gwangju, Seoul, Anyang, Hwaseong-si, Seongnam
2022-04-05
Recruiting
AbbVie
Phase 3
768
Goyang-si, Seongnam, Suwon, Jinju, Yangsan, Cheongju-si, Seoul
2022-03-25
Active, closed
Pfizer
Phase 3
854
Namdong-gu, Hwasun Gun, Seongnam, Busan, Seoul, Daegu, Junggu
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Goyang-si, Seongnam, Songpagu, Seoul
2022-03-15
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Busan, Daegu, Gwangju, Goyang-si, Anyang, Hwasŏng, Seongnam, Seoul
2022-03-15
Active, closed
Eli Lilly and Company
Phase 3
368
Seongnam, Seoul, Daegu
2022-03-11
Recruiting
Joon Bum Kim
Phase 4
1,300
Bucheon-si, Busan, Daegu, Gangneung, Gwangju, Seongnam, Seoul, Suwon
2022-02-21
Recruiting
Takeda
Phase 3
120
Daegu, Incheon, Seongnam, Seoul
2022-02-10
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
Busan, Daegu, Daejeon, Dongan, Goyang-si, Jeonju, Seongnam, Seoul
2022-01-15
Active, closed
Eli Lilly and Company
Phase 3
152
Hwasun, Goyang-si, Seongnam, Busan, Seoul, Deagu
2021-12-20
Recruiting
AbbVie
Phase 1
694
Goyang-si, Seongnam, Seoul
2021-11-01
Active, closed
Boehringer Ingelheim
Phase 1
151
Incheon, Seongnam, Seoul
2021-10-18
Active, closed
AbbVie
Phase 1
520
Busan, Seongnam, Jinju, Cheongju-si, Seoul
2021-10-13
Active, closed
Pfizer
Phase 3
77
Namdong-gu, Goyang-si, Seongnam, Seoul
2021-09-29
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Cheonan-si, Cheongju-si, Gangwon-do, Gyeonggi-do, Incheon, Namdong-Gu, Seongbuk-Gu, Seongnam
2021-08-27
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Cheonan-si, Seongnam, Seoul
2021-08-25
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
110
Seongnam, Cheongju-si, Seoul
2021-08-19
Active, closed
JOTEC GmbH
Observational
114
Seongnam, Seoul
2021-08-01
Active, closed
Boehringer Ingelheim
Phase 1
554
Chungju, Seongnam, Seoul
2021-07-02
Active, closed
Idience Co., Ltd.
Phase 1/2
87
Jeonju, Busan, Seongnam, Seoul
2021-06-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Goyang-si, Seongnam, Seoul
2021-06-18
Active, closed
Daiichi Sankyo
Phase 3
490
Daegu, Hwasun, Seongnam, Seoul
2021-05-21
Active, closed
Pfizer
Phase 3
599
Goyang-si, Hwasun-gun, Seongnam, Daegu, Seoul
2021-05-12
Active, closed
ALX Oncology Inc.
Phase 2
172
Cheongju-si, Daegu, Incheon, Seongnam, Seongnam-si, Seoul
2021-05-10
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
DrugPhase 2
enGene, Inc.
Phase 1/2
350
Seongnam, Hwasun, Seoul
2021-04-22
Active, closed
ALX Oncology Inc.
Phase 2
189
Cheongju-si, Daegu, Daejeon, Gyeonggi-do, Incheon, Seongnam, Seoul, Suwon
2021-04-02
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
Seongnam, Seoul
2021-03-22
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Goyang, Seongnam, Seoul, Yangsan
2021-03-18
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Songpa-gu, Cheongju-si, Daegu, Goyang-si, Seongnam, Seoul
2021-02-02
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
Seongnam, Seoul
2020-12-16
Active, closed
Gilead Sciences
Phase 3
331
Busan, Seongnam, Seoul, Suwon
2020-11-23
Recruiting
NRG Oncology
Not applicable
1,956
Dalseo-gu, Seoul, Seongnam, Gwangmyeong
2020-09-01
Active, closed
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma
DrugsOregovomab·Paraplatin·Taxol·Paclitaxel
CanariaBio Inc.
Phase 3
615
Goyang, Seongnam, Seoul, Soeul
2020-08-25
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Taebuk, Goyang-si, Seongnam, Seoul
2020-02-11
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Bucheon-si, Daegu, Seongnam, Seoul
2019-10-03
Active, closed
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8
DrugsParaplatin·Taxol·Letrozole·Paclitaxel
NRG Oncology
Phase 3
450
Goyang-si, Seoul, Seongnam, Daegu, Incheon
2019-09-20
Active, closed
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
DrugsParaplatin·Taxol·Keytruda·Paclitaxel
National Cancer Institute (NCI)
Phase 3
813
Dalseo-gu, Seoul, Seongnam, Daegu
2019-08-22
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Cheonju, Goyang, Seongnam, Seoul, Suwon
2019-07-09
Active, closed
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
NCT03969823Locally Advanced or Metastatic NSCLC
DrugsTagrisso·Osimertinib
Seoul National University Hospital
Not applicable
148
Seongnam, Seoul
2019-05-23
Recruiting
Aptose Biosciences Inc.
Phase 1/2
240
Seoul, Daegu, Pusan, Seongnam
2019-03-11
Active, closed
Young-Suk Lim
Phase 4
780
Daegu, Seongnam, Seoul, Ulsan
2019-02-18
Active, closed
AbbVie
Phase 2
270
Goyang-si, Seongnam, Suwon, Yangsan, Incheon, Hwasun-gun, Cheongju-si, Seoul
2018-10-10
Recruiting
Korean Heart Failure Registry III
NCT04329234Acute Heart Failure
Seoul National University Bundang Hospital
Observational
10,000
Seongnam
2018-10-01
Recruiting
Seung-Jung Park
Observational
500
Bucheon-si, Daegu, Daejeon, Gwangju, Pusan, Seongnam, Seoul
2018-09-04
Active, closed
AbbVie
Phase 3
1,242
Busan, Daejeon, Guri-si, Seongnam, Suwon, Seoul, Daegu
2018-08-28
Active, closed
Genoss Co., Ltd.
Observational
1,118
Seongnam
2018-04-19
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
Seongnam, Seoul, Daejeon
2018-04-17
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Ansan-si, Busan, Daegu, Gyeonggi-do, Hwaseong-si, Seongnam, Seongnam-si, Seoul
2018-04-13
Active, closed
Gilead Sciences
Phase 3
340
Bucheon-si, Busan, Daegu, Seongnam, Seoul, Songpa-Gu
2017-12-12
Active, closed
Samsung Medical Center
Not applicable
240
Goyang-si, Pusan, Seongnam, Seoul
2017-10-20
Active, closed
Eli Lilly and Company
Phase 3
5,637
Cheongju-si, Cheonan-si, Incheon, Namdong-gu, Goyang-si, Seongnam, Busan, Haeundae-gu
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
Goyang-si, Seongnam, Seoul
2017-05-02
Active, closed
AbbVie
Phase 3
950
Busan, Guri-si, Seongnam, Suwon, Seoul, Daegu
2017-01-31
Recruiting
Samsung Medical Center
Observational
797
Incheon, Seongnam, Seoul, Taebuk, Ulsan
2016-06-10
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Taxol
National Cancer Institute (NCI)
Phase 2/3
582
Dalseo-gu, Seongnam, Incheon, Seoul
2016-05-03
Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
NCT02708134Cardiac Arrest, Cardiopulmonary Arrest
Children's Hospital of Philadelphia
Observational
7,000
Seongnam
2016-05-02
Active, closed
Eli Lilly and Company
Phase 3
545
Cheongju-si, Seongnam, Suwon, Jinju, Seoul, Ulsan
2015-05-06
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Goyang-si, Seongnam, Seoul
2014-11-26
Active, closed
Eli Lilly and Company
Phase 3
493
Incheon, Goyang-si, Seongnam, Seoul, Daegu, Ulsan
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
669
Cheongju-si, Incheon, Namdong-gu, Seongnam, Seoul, Ulsan
2014-07-22
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Daegu, Gwangju, Pusan, Seongnam, Seoul
2013-10-14
Active, closed
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT01272037Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
DrugsTamoxifen Citrate·Tamoxifen·Exemestane·Anastrozole
National Cancer Institute (NCI)
Phase 3
5,018
Goyang-si, Seongnam, Seoul
2011-02-28
Active, closed
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
DrugsHD204·Bevacizumab-awwb·BP102·Zirabev
National Cancer Institute (NCI)
Phase 3
1,052
Dalseo-gu, Goyang-si, Seoul, Seongnam, Incheon, Suwon
2007-12-06
Rows per page Showing 1–205 of 205
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seongnam

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 205 of those studies with a site in Seongnam.

How many clinical trials are recruiting in Seongnam?

105 of the 205 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 4 have not yet opened recruitment, 94 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seongnam), 205 studies
PhaseStudiesRecruitingShare
Phase 31034550.2%
Phase 120129.8%
Phase 21898.8%
Phase 1/217108.3%
Observational15107.3%
Not applicable1265.9%
Phase 2/31285.9%
Phase 4853.9%

Most active sponsors

Lead sponsors with the most studies (Seongnam)
Lead sponsorStudiesRecruiting
Eli Lilly and Company198
Merck Sharp & Dohme LLC165
AbbVie134
Pfizer127
Boehringer Ingelheim117
Bristol-Myers Squibb118
Daiichi Sankyo85
Seoul National University Hospital74
Gilead Sciences52
National Cancer Institute (NCI)50
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.